Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of ACT-389949 in Healthy Subjects
NCT02099201Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-389949 in Inflammatory Disorders (7 arms), sponsored by Idorsia. Primary endpoints: Change from baseline up to end of study in supine systolic blood pressure up to 13 days, Change from baseline up to end of study in supine diastolic blood pressure up to 13 days and 9 more. Started Nov 2012; status: completed.
02
Drugs
ACT-389949
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT02099201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099201.